



**FOR IMMEDIATE RELEASE**

**AdvanSource Biomaterials to Showcase its Innovative Technology  
at MD&M West Expo on February 10-12**

**Leading Edge Polymers Exhibited at Booth # 2074**

**WILMINGTON, MA, February 4, 2008** -- AdvanSource Biomaterials Corporation (NYSE **Alternext US: ASB**), a leading developer of advanced polymer materials for a broad range of medical devices announced today that it will be showcasing its innovative technology at the world's largest medical OEM event -- Medical Design & Manufacturing (MD&M West) -- that will take place February 10-12 at the Anaheim Convention Center in California.

“As a comprehensive resource for the medical device community, MD&M West is a key venue for informing medical device companies and OEM manufacturers about AdvanSource Biomaterials’ performance polymers and the targeted end-product optimization they deliver. We will be showcasing our new product extensions, specifically our newly expanded solution-based polymer capabilities as well as our antimicrobial enhancement lines. We are excited by the opportunities our new market driven product lines provide and the opportunity to continue broadening our range of capabilities to meet the medical industry’s evolving material needs,” noted Vice President Sales and Marketing Kristine Carroll.

In addition to Ms. Carroll, AdvanSource President Michael Adams, Dr. Andrew Reed, Vice President of Science and Technology and members of the marketing and R&D teams, will be at booth # 2074 to demonstrate the Company’s leading edge technology, notably products such as **ChronoFlex®**, **HydroMed™**, and **HydroThane™** which have been developed to overcome a wide range of design and functional challenges, from the need for dimensional stability, ease of manufacturability and demanding physical properties to overcoming environmental stress cracking (ESC) and providing heightened lubricity for ease of insertion.

The Company will also showcase its **antimicrobial extension lines** that compliment the ChronoFlex® and HydroMed™ product families. Through proprietary manufacturing techniques, the Company has produced materials which allow for full homogenous dispersion throughout the polymer, thus resulting in long lasting and consistent activity and the prevention of leaching. The end result being a technologically advanced antimicrobial material which reduces the potential for foreign body patient infections, has a higher kill rate and is less susceptible to bacterial growth and biofilm formations. AdvanSource has developed a drug-free, antimicrobial technology targeting the minimization of MRSA, among other clinical infections associated with medical devices.



**About AdvanSource Biomaterials Corporation**

AdvanSource Biomaterials Corporation manufactures advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. AdvanSource's business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. The Company is conducting a clinical trial for regulatory approval at two sites in Europe for its CardioPass™ synthetic coronary bypass graft. More information about AdvanSource is available at its website: [www.advbiomaterials.com](http://www.advbiomaterials.com)

**For Further Information Contact:**

Khristine Carroll  
VP Sales & Marketing  
AdvanSource Biomaterials  
978 657-0075  
info@advbiomaterials.com

Eric Walters  
Vice President & CFO  
CardioTech International, Inc.  
978-657-0075  
general-info@cardiotech-inc.com

**Press**

Sylvia Dresner  
Senior Vice President  
VMW Corporate &  
Investor Relations  
212-616-6161